Rationale: Pulmonary arterial hypertension (PAH) is a lethal syndrome characterized by pulmonary vascular obstruction caused, in part, by pulmonary artery smooth muscle cell (PASMC) hyperproliferation. Mitochondrial fragmentation and normoxic activation of hypoxia-inducible factor-1␣ (HIF-1␣) have been observed in PAH PASMCs; however, their relationship and relevance to the development of PAH are unknown. Dynaminrelated protein-1 (DRP1) is a GTPase that, when activated by kinases that phosphorylate serine 616, causes mitochondrial fission. It is, however, unknown whether mitochondrial fission is a prerequisite for proliferation.
tive phenotype in PAH PASMCs (human and rodent) is associated with normoxic activation of HIF-1␣ and fragmentation of the mitochondrial network. 7 Normoxic activation of HIF-1␣ in human PAH occurs in PASMCs 4, 7 and endothelial cells. 8 HIF-1␣ activation can result from the redox changes initiated by epigenetic silencing of superoxide dismutase-2 in PAH, 4 consistent with previous descriptions of redox regulation of HIF-1␣. 9, 10 Activated HIF-1␣ suppresses mitochondrial oxidative metabolism (by increasing the expression of pyruvate dehydrogenase kinases, thereby blocking pyruvate uptake into the Krebs cycle) 11 while simultaneously upregulating enzymes and transporters that favor glycolysis (ie, hexokinase-2 and the glucose transporter-1). Targeting these mitochondrial metabolic abnormalities in PAH; using the pyruvate dehydrogenase kinase inhibitor dichloroacetate reduces glycolysis, restores oxidative metabolism, and regresses PAH in several experimental models. [12] [13] [14] This demonstrates the susceptibility of PAH to mitochondrial metabolic therapies. HIF-1␣ is activated early in experimental models of PAH and leads to a pulmonary glycolytic pattern that can be detected with a 18 F-fluoro-deoxyglucose positron emission tomography scan. This glycolytic switch is reversible with therapies including pyruvate dehydrogenase kinase inhibitors and Gleevec. 15 However, the link between HIF-1␣, mitochondrial fragmentation, and cell proliferation is unknown.
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Mitochondria exist in a dynamic network comprising individual organelles that continuously join (fusion) and fragment (fission). The GTPases mitofusin-1 (MFN1), mitofusin-2 (MFN2), and optic atrophy-1 regulate fusion. Conversely, fission-1 and dynamin-related protein-1 (DRP1) mediate mitochondrial fission. 16 The activity of DRP1 results from phosphorylation by regulatory kinases, including the mitosis regulator, cyclin B1/cyclin-dependent kinase 1 (CDK1), which causes mitotic phosphorylation of serine 616 and activation of DRP1. On activation, DRP1 moves from the cytosol to the mitochondria, where it assembles in multimers that constrict and divide the mitochondria. Conversely, phosphorylation of DRP1 at serine 637, by protein kinase A, inhibits fission. 17, 18 Here, we determine the molecular basis for mitochondrial fragmentation in PAH and its relationship to HIF-1␣, and assess whether mitochondrial fission offers a novel antiproliferative therapeutic target in PAH. Studies are conducted in human PASMCs and lung sections from PAH and control patients and in three rodent models of PAH, including a model induced by chemical activation of HIF-1␣. We demonstrate that HIF-1␣ activation is a proliferative stimulus that causes DRP1-mediated mitochondrial fission. In vivo HIF-1␣ activation (by cobalt) is sufficient to produce PAH in rats and Mdivi-1, a small-molecule DRP1 inhibitor, 19 restores mitochondrial fusion and reduces the hemodynamic and histological severity of PAH in this model. Increased fission in PAH PASMC reflects DRP1 activation by cyclin B1/CDK1 activity and accompanies cell-cycle progression from G2 to mitosis. We show that fission is required for normal cell division and that Mdivi-1 slows proliferation by locking mitochondria in fusion and inhibiting cell-cycle progression, causing G2/M arrest, as we recently also observed in lung cancer cells. 20 Mdivi-1 also has antiproliferative therapeutic benefit in monocrotaline-induced and hypoxia-induced pulmonary hypertension. We conclude that normoxic activation of HIF-1␣ creates a fissogenic proliferative milieu in PAH. Cyclin B1/CDK1, which is upregulated in PAH, coordinates mitosis and mitochondrial fission, permitting rapid proliferation; conversely, inhibition of mitotic fission causes cellcycle arrest and regresses PAH. Thus, mitotic fission is a checkpoint that can be therapeutically targeted by inhibiting DRP1 in hyperproliferative syndromes.
Methods

Human Lung Samples
Detailed Methods are provided in the Online Supplement. Paraffinembedded tissue sections and fresh tissue for PASMC isolation were obtained from autopsied patients with idiopathic PAH or control patients without PAH (Online Table I ).
Animal Studies
The University of Chicago Animal Care Committee approved all protocols. Male Sprague-Dawley rats were purchased from Charles Rivers Laboratories (Wilmington, MA). To induce pulmonary hypertension in rats, we injected 2 mg CoCl 2 intraperitoneally per day for 4 weeks (Sigma Aldrich). This dose was well-tolerated and did not induce mortality. Higher doses caused death or severe lethargy. Control rats received saline injections. Other animal models for PAH were chronic hypoxia (10% oxygen) and monocrotaline (60 mg/kg intraperitoneal). The DRP1 inhibitor Mdivi-1 (Enzo Life Sciences) was dissolved in DMSO and injected at a dose based on the literature (50 mg/kg) 21 for prevention studies (weekly injections for CoCl 2 and biweekly injections for chronic hypoxia), whereas five daily injections were administered 3 weeks after monocrotaline injection for regression studies. Control animals received intraperitoneal DMSO injections.
Immunoblotting and Immunofluorescence
Immunoblotting was performed on 25 g of protein from PASMCs. The primary antibodies used were anti-cyclin B1 (Santa Cruz Biotechnology), anti-cyclin E (Cell Signaling Technology), anti-DRP1 (Novus Biologicals), anti-phospho Ser616 DRP1 (Cell Signaling Technology), anti-phospho Ser637 DRP1 (Cell Signaling Technology), anti-HIF-1␣ (Novus Biologicals), anti-smooth muscle 
Small Interfering RNA Treatment of PASMCs
For small interfering RNA (siRNA) treatment, PASMCs were grown to approximately 80% confluence and then transfected using oligofectamine (Invitrogen) and 25 nmol/L validated Silencer Select siRNAs (Applied Biosystems). After 4 hours, normal culture medium was added and gene knockdown was assessed after 48 hours using quantitative reverse transcription polymerase chain reaction and immunocytochemistry. For each experiment there was a scrambled siRNA control (Applied Biosystems).
Live Cell Imaging to Assess Mitochondrial Networks
Mitochondria of live PASMCs were imaged with a Zeiss 510META confocal laser scanning microscope equipped with an environmental chamber to maintain humidity, 37°C, and 5% CO 2 . We used coexpression of mitochondrial matrix-targeted photoactivatable green fluorescent protein (GFP) (a kind gift of Dr. Richard Youle, National Institutes of Health) 22 and a mitochondrial matrix-targeted DsRed Protein (mito-DsRed, a kind gift of Dr Michael Frohman, Stony Brook University) 23 to assess the degree of mitochondrial connectivity in live cells. PASMCs were transfected using Fugene HD transfection reagent (Roche). After acquiring three control images, mitochondrial-targeted photoactivatable green fluorescent protein was photoactivated with 10 passes of the two-photon laser (set to 700 nm) in a confined 200ϫ60-pixel area. Photoactivated GFP was measured at 488 nm excitation and 500 to 550 nm emission. For assessing mitochondrial morphology in the whole cell, we used a mitochondrial matrix-targeted GFP protein (a kind gift of Dr Michael Frohman, Stony Brook University). 23 
Image Analysis of Mitochondrial Morphology
Two recently validated techniques were used for assessing mitochondrial morphology in the whole cell: measurement of the mitochondrial fragmentation count and the mitochondrial networking factor. 20 Briefly, images of mitochondrial matrix-targeted green fluorescent protein-transfected PASMCs were obtained, thresholded, and binarized to identify mitochondrial segments using ImageJ (National Institutes of Health). The mitochondrial fragmentation count was calculated by normalizing the number of individual mitochondria to the entire mitochondrial pixel count. 20 To quantify functional networking of the mitochondria, PASMCs were transfected with mitochondrial-targeted photoactivatable green fluorescent protein and mitochondrial-targeted DsRed protein. The extent of mitochondrial networking is reflected in the diffusion of the photoactivated mitochondrial GFP away from the site of photoactivation, as measured after 17.6 seconds using ImageJ (National Institutes of Health). A highly interconnected network allows the photoactivated GFP to distribute in a larger area, resulting in a higher mitochondrial networking factor. 20
Replication-Deficient Adenoviruses
The HIF-1␣ dominant-negative adenovirus was constructed using a plasmid from Dr Jian Chen (Hokkaido University, Japan). 24 Viral methodology is described in the Online Supplement.
Proliferation Assay
Proliferation was quantified using the Click-It EdU kit according the manufacturer's instructions (Invitrogen).
Transmission Electron Microscopy
Freshly isolated pulmonary arteries (third-order and fourth-order) were fixed and processed for electron microscopy (Online Supplement). Images were collected using a scanning transmission electron microscope at 300 KV (Tecnai F30; FEI) with a high-performance Gatan charge-coupled device camera. 
Measurement of
Supplemental Methods
Human and rat PASMC culture, quantitative reverse transcription polymerase chain reaction, O 2 consumption and metabolic measurements, electrophysiology, cytosolic calcium measurements, hemodynamic measurements, and histology were performed as previously described, 4, 26 and details are in the Online Supplement.
Results
DRP1-Mediated Mitochondrial Fragmentation in Human PAH PASMCs
Mitochondria are more fragmented in PASMCs from idiopathic PAH patients compared with control PASMCs ( Figure  1A ). Quantitative reverse transcription polymerase chain reaction for the genes that regulate mitochondrial fission and fusion 16 shows a profile that favors fission (increased DRP1 and fission-1 and decreased MFN2; Figure 1B ). Optic atrophy-1 and MFN1 expression are unchanged (Online Figure IA) . We focused on the role of DRP1 because preliminary data indicated that Mdivi-1, a small-molecule inhibitor of DRP1, substantially rescues the mitochondrial network and slows proliferation. Expression of total and activated DRP1 (phosphorylated at Ser616) are upregulated in PAH PASMC ( Figure 1C-E) . Direct inhibition of CDK1, using 10 mol/L of the specific inhibitor RO-3306, 27 significantly reduces DRP1 Ser616 phosphorylation, implicating CDK1 as the key kinase driving DRP1 activation in PAH. In contrast, inhibition of other putative mediators of DRP1 phosphorylation, such as calmodulin, with 5 mol/L W7 or calcium/calmodulindependent protein kinase II, with 20 mol/L KN93, has no effect on DRP1 Ser616 phosphorylation ( Figure 1E ). Serum withdrawal (like CDK1 inhibition) reduces both the percentage of PASMCs with DRP1 Ser616 phosphorylation and the expression of the G2/mitotic-specific cyclin B1 in PAH PASMCs ( Figure 1E -F), indicating that external growth factors/mitogens promote DRP1 activation. Using a FRET biosensor for cyclin B1/CDK1, we confirmed that increased levels of cyclin B1 in PAH PASMCs translate into higher cyclin B1/CDK1 activity ( Figure 1G ).
Mitochondrial networking, measured using the mitochondrial networking factor, is decreased in human PAH PASMC, and this is reversed by 25 mol/L Mdivi-1 ( Figure 1H ). Online Movies I to III show representative 8-minute time-lapse movies of control, PAH, and PAH plus Mdivi-1-treated PASMCs immediately before and after photoactivation, documenting the more rapid spread of the signal in cells treated with Mdivi-1.
Molecular or Pharmacological DRP1 Inhibition Blocks Cell-Cycle Progression
Compared to control human PASMCs, PAH PASMCs have increased proliferation rates at baseline, confirming the persistence of their hyperproliferative phenotype in vitro. DRP1 inhibition by Mdivi-1 causes a dose-dependent reduction in proliferation rates ( Figure 2A ). The antiproliferative effects of Mdivi-1 are attributable to induction of cell-cycle arrest in the G2/M phase ( Figure 2B , Online Figure IIA ), suggesting that cell-cycle progression is dependent on fission of mitochondria. To exclude nonspecific effects of Mdivi-1, we used siRNA directed against DRP1 and found a similar reduction in proliferation ( Figure 2C ) attributable to accumulation of PASMCs at the G2/M phase of the cell cycle ( Figure 2D ). To more exactly establish at which point the cell cycle is interrupted, we used immunoblotting to assess whether CDK1 activation is altered by Mdivi-1. CDK1 activation Expression was normalized to actin for each sample. D, More PAH PASMCs are positive for DRP1 Ser616 phosphorylation than control PASMCs. *PASMCs with DRP1 phosphorylated at Ser616. Scale barϭ100 m. E, High levels of DRP1 Ser616 phosphorylation in PAH PASMCs vs control PASMCs. Only direct inhibition of CDK1 with 10 mol/L RO-3306 and 16 hours of serum withdrawal (indicated by "-FBS" on the graph) decrease Ser616 phosphorylation levels. Inhibition of calmodulin with 5 mol/L W7 or calcium/calmodulin kinase II with 20 mol/L KN93 have no effect on DRP1 Ser616 phosphorylation. Approximately 100 PASMCs were counted for each group. F, Cyclin B1 expression was measured with flow cytometry and was significantly higher in PAH PASMCs compared with control PASMCs. Serum withdrawal ("-FBS") reduces cyclin B1 levels in PAH PASMCs. G, Activity of the cyclin B1/CDK1 complex was measured using a biosensor Fö rster resonance energy transfer (FRET) probe. A higher yellow (YPet) over cyan (mCerulean) emission ratio indicates increased cyclin B1/CDK1 activity. PAH PASMCs have a higher activity compared with control PASMCs (nϭ10 -11 cells/group). H, Photoactivation experiments confirm the decreased mitochondrial networking in PAH PASMCs. The mitochondrial networking factor (MNF) is lower in human PAH PASMCs and Mdivi-1 (25 mol/L), an inhibitor of DRP1, reverses the fragmented phenotype and increases the MNF, demonstrating that increased DRP1 activity is the major determinant of the fragmented mitochondrial morphology in PAH. Scale barϭ10 m.
during mitosis depends on dephosphorylation of Thr14 and Tyr15. 28 This dephosphorylation is not impaired by Mdivi-1 ( Figure 2E ), suggesting that cell-cycle arrest occurs specifically in prometaphase (between late G2 and metaphase), because this is the last phase in which cells have dephosphorylated CDK1. Subsequently, CDK1 becomes phosphorylated/inactivated attributable to proteosomal degradation of cyclin B1, 29 and this was not observed with Mdivi-1. Mdivi-1-induced G2/M arrest is reminiscent of the state observed with cell synchronization by the microtubule assembly inhibitor, nocodazole. Therefore, we synchronized PASMCs in prometaphase with 50 ng/mL nocodazole for 16 hours. Synchronization was confirmed by an increase in cyclin B1-positive PASMCs ( Figure 2F ). After removal of nocodazole, PAH cells rapidly move through mitosis, evident in parallel decreases in cyclin B1 levels and DNA content; however, Mdivi-1 prevents decreases in cyclin B1 levels ( Figure 2F ), confirming that Mdivi-1 specifically blocks cell-cycle progression beyond prometaphase in PAH PASMCs.
Mdivi-1 binds to an allosteric site on DRP1 and thereby blocks a conformational change required for self-assembly. 19 Because self-assembly is downstream of DRP1 Ser616 phosphorylation, Mdivi-1 should not decrease DRP1 Ser616 phosphorylation. Mdivi-1 actually increases DRP1 Ser616 phosphorylation (Online Figure IB, C) , consistent with the observed increased CDK1 activation in response to Mdivi-1 ( Figure 2E ). Thus, Mdivi-1 is not interfering with CDK1-mediated phosphorylation of DRP1 Ser616. Recently, Mitra et al 30 described increased levels of the S-phase promoting cyclin E in response to Mdivi-1, which we confirmed (Online Figure IIB) . They also noted increased entry into S-phase, which supports our finding that Mdivi-1 inhibits proliferation mainly by inhibiting a G2/M checkpoint in the cell cycle.
DRP1 Activation in Human PAH Pulmonary Arteries
We obtained human lung tissue from five autopsied idiopathic PAH patients and five age-matched controls (patient characteristics in Online Table I ) and confirmed the presence of plexiform lesions and increased pulmonary artery muscu- larization ( Figure 3A) . Plexiform lesions and muscularized pulmonary arteries from idiopathic PAH patients have 10%Ϯ7% and 12%Ϯ3% increases in DRP1 expression, respectively, compared with arteries from normal subjects (Online Figure IIIA) . DRP1 Ser616 is clearly enriched in pulmonary arteries (versus lung parenchyma) in PAH and is greater in PAH versus control lungs ( Figure 3B) , consistent with the PASMC data ( Figure 1D-E) . Moreover, the G2/ mitotic-specific cyclin B1 is not only upregulated in PAH PASMCs but also activated, evident from its nuclear translocation ( Figure 3C ), which is in line with the increased cyclin B1/CDK1 activity measured in PAH PASMCs using a FRET biosensor ( Figure 1G ). Increased cyclin B1/CDK1 directly leads to DRP1 Ser616 phosphorylation. 31 Whereas endothelial cells stain strongly for the inhibitory Ser637 form of DRP1, we did not detect this form of DRP1 in the media of control or PAH lungs (Online Figure IIIB) and therefore focused on DRP1 Ser616 in subsequent experiments.
HIF-1␣ Activation Increases Proliferation and Glycolysis in Human PAH PASMCs
We confirmed that HIF-1␣ activation occurs in PASMCs in lungs from PAH patients but not in control patients ( Figure  4A ). Even when PAH PASMCs are cultured in vitro at oxygen concentrations of approximately 140 mmHg, most have HIF-1␣ activation, evident from its nuclear translocation, greatly exceeding the rate in control PASMCs ( Figure  4B ). Metabolically, HIF-1␣ activation increased glycolysis, as measured with a Seahorse Bioscience XF24 analyzer (Online Supplement). Compared with control PASMCs, we observed a more than three-fold higher lactate production rate and a two-fold lower ratio of oxygen consumption/lactate production in PAH versus control human PASMCs (Online Figure IVA) . The upregulated glycolysis is also evident in increased gene expression of glucose transporter-1, pyruvate dehydrogenase kinase-2, and pyruvate dehydrogenase kinase-4 (Online Figure IVB) . A, In contrast to normal human lungs, idiopathic PAH patients have pulmonary blood vessels with excessive pulmonary artery smooth muscle cell (PASMC) proliferation ("muscularization") and plexiform lesions, which both contribute to an obstruction of the pulmonary blood vessels. Analysis of pulmonary blood vessels with an external diameter Ͻ150 m demonstrates a significant thicker muscular coat. This, together with the presence of plexiform lesions in all the analyzed patients, confirms the diagnosis of PAH. Scale barϭ200 m. B, A significantly higher number of blood vessels stain positive for the active form of DRP1 (characterized by Ser616 phosphorylation) in human PAH vs control lungs. Approximately 150 blood vessels were analyzed in each group. Scale barϭ50 m. C, Cyclin B1, together with cyclin-dependent kinase 1, leads to phosphorylation of DRP1 on Ser616. Cyclin B1 staining was present in nonvascular tissues in control lungs, but was almost absent in the PASMC nuclei of small pulmonary arteries of control lungs. In contrast, there was clear nuclear accumulation (activation) of cyclin B1 in human PAH blood vessels. Approximately 120 PASMC nuclei were analyzed in each group. Scale barϭ50 m.
We next examined the consequences of HIF-1␣ activation on proliferation and metabolic function in human PASMCs. The importance of HIF-1␣ activation for proliferation was studied using chetomin, a small molecule that inhibits the interaction of HIF-1␣ with its p300 coactivator, preventing hypoxia-inducible gene transcription. 32 Chetomin caused minimal cell death ( Figure 4C) , consistent with the low doses (5-50 nmol/L) we used, relative to those reported in the literature. 33, 34 Chetomin dose-dependently inhibited proliferation ( Figure 4D ) and DRP1 Ser616 phosphorylation ( Figure 4E ).
HIF-1␣ Activation in Normal PASMCs Recapitulates the PAH Phenotype and Induces Mitochondrial Fragmentation
We used two chemically discrete HIF-1␣ activators (CoCl 2 and desferrioxamine) 35 to establish a direct relationship between normoxic HIF-1␣ activation and mitochondrial fragmentation in normal rat PASMCs. This approach avoids confounders, such as genetic abnormalities and upregulation of growth factor pathways that might exist in human PAH cells. CoCl 2 activated HIF-1␣ in most PASMCs (evident from nuclear accumulation of HIF-1␣; Online Figure VA ).
Whole-cell patch-clamp traces show a reduction in voltagegated K ϩ currents (Kv) with CoCl 2 , which is rescued with a HIF-1␣ dominant-negative virus (Online Figure VIA-B) . The reduced Kv currents lead to depolarization of the PASMC (lower E M ; Online Figure VIC ) and increased cytosolic calcium levels (Online Figure VID) . Both abnormalities can be prevented by overexpression of HIF-1␣ dominantnegative virus construct, confirming the role of HIF-1␣ in the current inhibition caused by ex vivo CoCl 2 treatment. These HIF-1␣-induced electrophysiological changes recapitulate those seen in PAH PASMCs. 7,36 -39 
HIF-1␣ Dependence of Cobalt-Induced Mitochondrial Fission
CoCl 2 (500 mol/L) rapidly induces mitochondrial fission, again mimicking PAH ( Figure 4F ). To exclude nonspecific effects of the chemical HIF-1␣ activators, we first showed that 50 g/mL cycloheximide, an inhibitor of protein translation, prevents cobalt or desferrioxamine-induced mitochondrial fragmentation. This indicates that protein synthesis is required for HIF-1␣-induced fission ( Figure 5A, B) . Next, we showed that HIF-1␣ siRNA largely prevents cobalt- 
. Hypoxia-inducible factor-1␣ (HIF-1␣) is activated in lungs and pulmonary artery smooth muscle cells (PASMCs) from pulmonary arterial hypertension (PAH) patients, which is necessary for proliferation and leads to mitochondrial fragmentation.
A, Immunohistochemistry for HIF-1␣ reveals that PAH patients have pulmonary blood vessels that stain positive in the media for HIF-1␣. Scale barϭ40 m. B, Cultured PASMCs from idiopathic PAH patients maintain elevated HIF-1␣ expression levels in vitro despite being cultured at ambient oxygen concentrations. Approximately 100 PASMCs were analyzed for each group. Scale barϭ100 m. C, Dose response of chetomin leads to only small changes in cellular morphology in human PASMCs. Scale barϭ200 m. D, Inhibition of HIF-1␣ signaling with chetomin leads to a dose-dependent reduction in proliferation in both control and PAH PASMCs. E, Chetomin dose-dependently reduces dynamin-related protein-1 (DRP1) Ser616 phosphorylation in human PASMCs. Approximately 250 nuclei were counted for each group. F, Activating HIF-1␣ with CoCl 2 (500 mol/L) leads to a rapid mitochondrial fragmentation, reminiscent of the fragmented morphology observed in PAH PASMCs.
induced fission, proving the fragmentation is attributable to HIF-1␣ activation ( Figure 5C ). Efficacy of HIF-1␣ siRNA is demonstrated in Online Figure VB and VC. Finally, we showed that cobalt increases the phosphorylation of DRP1 Ser616 ( Figure 5D ). Thus, cobalt-induced HIF-1␣ activation mimics the PAH phenotype described in Figure 1D .
Mdivi-1 Reverses HIF-1␣-Induced Mitochondrial Fragmentation
We used Mdivi-1 to confirm that the mitochondrial fragmentation observed after CoCl 2 -induced HIF-1␣ activation is dependent on DRP1. Mdivi-1 treatment (25 mol/L) not only normalizes mitochondrial morphology after CoCl 2 treatment ( Figure 5E -F) but also enhances networking, as demonstrated by the more rapid and broader spread of photoactivated, mitochondrial matrix-targeted GFP ( Figure 5E, G) . This is concordant with the effects of Mdivi-1 in human PAH PASMCs ( Figure 1H ).
Chronic Treatment With CoCl 2 Causes Experimental PAH
Because cobalt recapitulates many of the features of PAH PASMCs in culture, we determined whether activation of HIF-1␣ using cobalt would cause PAH in vivo. As expected, chronic cobalt treatment increased hematocrit, confirming that the selected dose of CoCl 2 was biologically active ( Figure 6A ). Moreover, cobalt decreased maximal walking distance ( Figure 6B ). Echocardiography confirmed that the pulmonary artery acceleration time, a measure of vascular compliance that is inversely related to pulmonary artery pressures, 26 
DRP1 Inhibition Attenuates Pulmonary Hypertension In Vivo
To determine whether inhibition of mitochondrial fission in vivo would attenuate cobalt-induced PAH, we coinjected 50 mg/kg Mdivi-1 (or the DMSO vehicle) on a weekly basis in rats receiving chronic CoCl 2 injections. Exercise capacity, which is reduced in cobalt-induced PAH, is normalized by Mdivi-1 treatment ( Figure 6B ). The pulmonary artery acceleration time increases significantly after Mdivi-1 treatment ( Figure  6C , Online Figure VIIA) . Similarly, Mdivi-1 significantly decreases pulmonary vascular resistance ( Figure 6D ). Mdivi-1 treatment decreases right ventricular hypertrophy ( Figure 6G ) and the percentage medial thickness of small pulmonary arteries, consistent with an antiproliferative effect ( Figure 6H, I ).
Mitochondrial Fragmentation In Vivo in Response to CoCl 2
To prove that the antiproliferative effects of Mdivi-1 in vivo reflected inhibition of fission, we performed transmission electron microscopy studies on pulmonary arteries isolated from control rats and rats receiving CoCl 2 or CoCl 2 plus Mdivi-1. These images demonstrate that mitochondrial fragmentation is present in vivo in the cobalt PAH model and that these morphological changes are reversed with Mdivi-1 ( Figure 6J ).
Mdivi-1 Attenuates the Development of Chronic Hypoxia-Induced Pulmonary Hypertension
We also studied whether similar benefits of Mdivi-1 therapy could be observed in additional experimental models of PAH. As shown in Figure 7A , Mdivi-1 prevents the decrease in exercise capacity caused by chronic hypoxia-induced pulmonary hypertension. Echocardiography confirms that Mdivi-1 -1 treatment (G) . Immunohistochemistry for von Willebrand factor (green) and smooth muscle cell actin (red) reveals that small precapillary resistance vessels in the lungs of CoCl 2 -treated animals have a thicker media compared with control lungs, and Mdivi-1 partially reverses this (H, I). Scale barϭ50 m. J, Electron microscopy imaging of pulmonary arteries derived from control animals and rats treated with CoCl 2 and CoCl 2 plus Mdivi-1. Pulmonary artery smooth muscle cells (PASMCs) were identified at a low magnification (5900ϫ) by their characteristic cytoplasmic phenotype, their close proximity to collagen fibers, and the absence of Weibel Palade bodies (upper panels, scale barϭ1 m). Higher-resolution images (25 000ϫ, lower panels, scale barϭ200 nm) were then acquired to measure mitochondrial size. Note the smaller mitochondrial size in the CoCl 2 rats and the normalization in the CoCl 2 plus Mdivi-1 rats.
improved pulmonary artery acceleration time (consistent with a reduction in pulmonary artery pressure) and tricuspid annular plane systolic excursion (indicating improved right ventricular function) while reducing right ventricular hypertrophy ( Figure 7A ). Mdivi-1 also has antiproliferative effects in the chronic hypoxia model. In line with our previous findings, we observed decreased muscularization and fewer proliferating PASMCs in rats treated with Mdivi-1 ( Figure  7B-D) .
Mdivi-1 Reduces Proliferation in the Monocrotaline Model of PAH
Having shown that Mdivi-1 can attenuate the development of CoCl 2 and chronic hypoxia-induced PAH, we tested Mdivi-1 as regression therapy in the monocrotaline model. More specifically, we wanted to test whether inhibiting fission reduces PASMC proliferation. Daily Mdivi-1 treatment was started 3 weeks after monocrotaline injection, when PAH is already established (confirmed by echocardiography), and continued for 5 days. This relative short treatment significantly improved tricuspid annular plane systolic excursion, and there were trends toward improved pulmonary artery acceleration time and reduced right ventricular hypertrophy, although neither achieved statistical significance (Online Figure VIIIA) . In addition, muscularization of small pulmonary arteries was significantly decreased by Mdivi-1 and there was a pronounced decrease in PASMC proliferation (Online Figure VIIIB) . HIF-1␣ activation also was present in the monocrotaline model (Online Figure VIIIC ).
Discussion
We demonstrate that the hyperproliferative diathesis of human PAH PASMCs reflects increased DRP1 expression and activation (Figures 1, 2) . The molecular mechanism of DRP1 activation in human PAH patients is increased DRP1 Ser616 phosphorylation ( Figure 1D , E, Figure 3B ), reflecting increased activation of the regulatory kinase of DRP1 (cyclin B1/CDK1). DRP1 Ser616 phosphorylation and fission can be induced in normal PASMCs by chemically activating HIF-1␣. The relevance of HIF-1␣-induced DRP-1 activation to PAH is evident in the discovery that cobalt-induced HIF-1␣ activation elicits PAH in normal rats and that PAH is attenuated by Mdivi-1. Notably, the hemodynamic benefits were associated with restoration of mitochondrial fusion in vivo ( Figure 6J ). The antiproliferative effects of blocking mitotic fission also are evident in two well-established models of pulmonary hypertension. By locking the mitochondria in fusion, Mdivi-1 and siDRP1 prevent mitotic fission and cause cell-cycle arrest in the G2/M phase (Figure 2A-D) , which is consistent with the recent demonstration that inhibition of DRP1 regresses lung cancer cell xenografts. 20 Thus, excessive fission, which occurs in human PAH PASMCs in vitro and in vivo, contributes to the disease by driving proliferation and can be therapeutically targeted. Mitochondrial morphology reflects the balance of fission and fusion. Fusion merges the contents of adjoined mitochondria, creating a homogenous network of elongated mitochondria, allowing the redistribution of mitochondrial DNA and proteins. 40 Conversely, fission is necessary during cell division to evenly distribute mitochondria between daughter cells. 31 Fission occurs when DRP1 is recruited from the cytoplasm to the mitochondrial surface, where it forms oligomeric complexes that hydrolyze GTP and mechanically constrict the mitochondria causing fragmentation. 41 Taguchi et al 31 showed that the interconnected mitochondrial network structures in interphase HeLa cells become fragmented in the early mitotic phase via cyclin B1/CDK1-mediated DRP1 phosphorylation. In the current study, we show that in human PAH there is both an upregulation of total and Ser616 phosphorylated DRP1. The profission phenotype is seen in lungs from patients with PAH and persists in human PAH PASMCs in culture ( Figure 1D , E, Figure 3B ). The elevation of cyclin B1 and CDK1, which coordinate mitosis and mitotic fission, is a major stimulus for Ser616 phosphorylation in PAH ( Figure 1F , G, Figure 3C ). Cell proliferation is driven by many factors in PAH, including elevated levels of mitogens and growth factors 6 and mutations of the bone morphogenetic protein receptor (in familial PAH). 42 In carefully controlled experiments, using molecular tools including siHIF-1␣ and a HIF-1␣ dominant-negative virus, we showed that HIF-1␣ activation is sufficient to confer a PAH phenotype on previously normal PASMCs (Online Figure VI) and to induce mitochondrial fission ( Figure 5 ). The increased HIF-1␣ in human PAH lungs ( Figure 4A ) persists in culture, despite PASMCs being cultured at ambient oxygen concentrations (approximately 140 mmHg). This is consistent with the recently described epigenetic suppression of mitochondrial superoxide dismutase, which is an upstream heritable cause of the HIF-1␣ activation and proliferation in human and fawn-hooded rat PAH that persist in cells in culture. 4 In addition, normoxic HIF-1␣ activation can be induced in aortic smooth muscle cells by growth factors such as serotonin and platelet-derived growth factor-BB. 43 HIF-1␣ activation causes a glycolytic shift that confers a proliferative advantage in PASMCs. Similar HIF-1␣-dependent glycolytic metabolic changes also occur in the endothelial cells of PAH patients. 8, 44 Proof that HIF-1␣ underlies the proliferation advantage comes from experiments in which HIF-1␣ inhibition by chetomin 32 reduces PASMC proliferation ( Figure 4D ). Activation of HIF-1␣ results in glycolytic metabolic changes that can be detected using lung 18 F-fluorodeoxy-glucose positron emission tomography scans. These glycolytic changes occur simultaneously with the development of pulmonary hypertension after monocrotaline administration and appear to be related to increased proliferation. 15 Reversing the glycolytic phenotype with dichloroacetate also regresses experimental PAH. 15 Our findings are consistent with the observations that HIF-1␣ haplo-insufficient mice are relatively protected from chronic hypoxic pulmonary hypertension, 45 whereas HIF-1␣ activation increases proliferation of human PASMCs in response to platelet-derived growth factor. 46 These data provide compelling evidence that HIF-1␣ activation contributes to disease progression in human PAH.
Whereas CoCl 2 clearly induces HIF-1␣ in PASMCs (Online Figure VA) , it is possible that nonspecific effects of cobalt contribute to our observations. Gene expression arrays in fibroblasts and carcinoma cells have shown that CoCl 2 and HIF-1␣ induce a common set of genes, but some genes are specifically induced by cobalt. 47, 48 Yet, desferrioxamine, another HIF-1␣ activator, 35 similarly leads to mitochondrial fragmentation (Figure 5A ) and, conversely, siRNA-mediated knockdown of HIF-1␣ prevents CoCl 2 -induced mitochondrial fragmentation ( Figure 5C ), indicating that mitochondrial fragmentation depends on HIF-1␣ activation. Moreover, changes in K ϩ currents, membrane potential, and cytoplasmic calcium concentrations induced by CoCl 2 are almost completely negated by adenoviral overexpression of a HIF-1␣ dominant-negative construct (Online Figure VI) , again suggesting that in PASMCs most effects of CoCl 2 are HIF-1␣-mediated. In addition, in vivo, CoCl 2 will induce HIF-1␣ in other tissues, as exemplified by increased hematocrit, which is dependent on renal erythropoietin production. Despite possible nonspecific effects, the net result of chronic CoCl 2 administration is pulmonary vascular remodeling ( Figure 6 ).
We acknowledge that although Mdivi-1 clearly improves mitochondrial networking both in human ( Figure 1H ) and rat PASMCs ( Figure 5E ), and in vivo ( Figure 6J ) it potentially could have off-target effects. However, knockdown of DRP1 expression by using a specific siRNA causes a similar arrest of PAH PASMC in the G2/M phase and has the same antiproliferative effects as Mdivi-1 on PAH PASMC ( Figure  2C, D) . Because Mdivi-1 is currently the only commercially available small-molecule inhibitor of mitochondrial fragmentation, the development of other inhibitors will be necessary to confirm the specificity of our findings. Even though DRP1 knockout mice have been generated, they die at approximately embryonic day 12.5, precluding their use to study the role of DRP1 in the development of PAH. 49 In patient-derived PAH PASMCs and cobalt-treated PASMCs, Mdivi-1 prevents mitochondrial fragmentation and enhances fusion ( Figure 1H , Figure 5E -G). Mdivi-1 or knockdown of DRP1 prevents proliferation in human PAH PASMCs (Figure 2A, C) . The notion that mitochondrial fragmentation is essential for cell-cycle progression past the G2/M checkpoint is an important and possibly controversial discovery. In support of our findings, gene therapy with Mitofusin-2, which causes mitochondrial fusion, also slows smooth muscle cell proliferation in systemic arterial injury. 50 Moreover, DRP1 activation recently has been shown to be crucial to the hyperproliferative phenotype in lung cancer, and Mdivi-1 is therapeutic in regressing tumors in a xenotransplantation model. 20 More study is required to determine whether mitotic division of organelles (not just mitochondria) is relevant to proliferative disorders. Supporting this notion, blocking Golgi fragmentation prevents progression through mitosis. 51 Interestingly, CDK1 is involved in controlling Golgi fragmentation as well. 52 Electron microscopy confirms that CoCl 2 induces mitochondrial fragmentation in vivo ( Figure 6J ), and chronic cobalt administration leads to pulmonary hypertension in line with previous publications that describe its ability to increase hematocrit, pulmonary hypertension, and right ventricular hypertrophy in rats, 53 and right ventricular hypertrophy in broiler chickens. 54 Importantly, Mdivi-1 already has been shown to protect against ischemia-induced kidney damage and cardiac ischemia-reperfusion injury. 21, 55 For the first time to our knowledge, we used Mdivi-1 for long-term treatment (during the 4 weeks of CoCl 2 administration) and observed that it is well-tolerated and significantly improves exercise capacity and reduces pulmonary vascular resistance and right ventricular hypertrophy ( Figure 6B-G) . Moreover, muscularization of the pulmonary small blood vessels is attenuated by Mdivi-1 treatment, consistent with its antiproliferative effects on PAH PASMCs ( Figure 6H, I ). We only looked at the effect of Mdivi-1 on PASMC proliferation, and it is possible that Mdivi-1 could influence other cell types as well. However, we did observe increased hematocrit in CoCl 2 rats treated with Mdivi-1, indicating that hematopoietic stem cell proliferation is not or is only minimally impaired. Moreover, impaired intestinal stem cell proliferation would result in impaired nutrient absorption and weight loss, which we did not observe. After intraperitoneal injection, Mdivi-1 is taken-up in the mesenteric vein and transported to the right ventricle and subsequently to the pulmonary circulation. Therefore, Mdivi-1 concentrations are expected to be higher in the pulmonary vascular bed compared with other vascular beds. A similar mechanism is responsible for the relative pulmonary specificity of monocrotaline-induced pulmonary hypertension. Future pharmacological studies are necessary to evaluate tissue distribution and retention times of Mdivi-1. Mdivi-1 reduces PASMC proliferation in both monocrotaline and chronic hypoxic pulmonary hypertension (Figure 7 , Online Figure VIII) . Therefore, it is reasonable to anticipate that Mdivi-1 is more effective in preventing than in reversing PAH. Thus, inhibition of mitochondrial fission may have broad therapeutic benefit in preventing disease progression in various forms of PAH. Future research is necessary to elucidate the role of fission-1 and MFN-2 in the hyperproliferative phenotype of PAH.
In conclusion, HIF-1␣-stimulated DRP1-mediated mitochondrial fission leads to increased proliferation in human PAH PASMCs. This is the first direct evidence that an acquired abnormality of mitochondrial fission contributes to the maintenance of human PAH and demonstrates the feasibility of targeting mitochondrial dynamics as a therapeutic option for PAH. Taken together, our data indicate that mitotic fission is required for rapid proliferation and, conversely, that locking the mitochondria in a networked state prevents mitotic fission, causing cell-cycle arrest. A schematic representation of our conclusions is provided in Figure 8 . Our findings have great therapeutic potential in PAH, evidenced by the effective and well-tolerated response to Mdivi-1 in the human PAH PASMC and several experimental models of pulmonary hypertension (Figures 6, 7 , and Online Figure  VIII ). This work also demonstrates an important interaction between the mitochondrial cycle and the cell cycle, which perhaps can be exploited in other proliferative disorders, such as cancer.
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None. Figure 8 . Schematic representation of how the cell and mitochondrial cycles interact. Activation of the mitochondrial GTPase dynamin-related protein-1 (DRP1) reflects regulatory kinases (cyclin B1/CDK1) that respond to signals from growth factors. In pulmonary hypertensive patients, cyclin B1 levels are elevated leading to activation of DRP1. By inhibiting fission (which is required for mitochondrial division), the cell cycle is halted, causing cells to be locked in G2/M arrest. The intersection of the mitochondrial and cell cycles is cyclin B1/CDK1-mediated mitotic fission, and this exposes an "Achilles heel" for rapidly proliferating cells that can be therapeutically targeted.
Mortality in PAH remains high despite current vasodilator therapies. Excessive proliferation of PASMCs contributes to PAH by obstructing the vasculature, suggesting that antiproliferative therapies may be therapeutic. This study explores two previous observations associated with hyperproliferation of PAH PASMCs: normoxic activation of HIF-1␣ and mitochondrial fragmentation. PASMC mitochondria exist in dynamic networks regulated by the balance between mitochondrial fusion and fission. Mitochondria divide (fission) during cell division, allowing equitable distribution of these organelles to daughter cells. Fission and mitosis are coordinated by the cell-cycle regulator cyclin B1-CDK1. Here, we identify HIF-1␣-related mechanism of mitochondrial fission in PAH. In human and experimental PAH, excessive activation of the GTPase DRP1 promotes mitochondrial fission. Conversely, inhibition of mitochondrial fragmentation arrests cells in the G2/M phase of the cell cycle and slows PASMC proliferation in experimental PAH, identifying mitochondrial fission as an important mitotic checkpoint. These findings shed light on the coordination between cell division and mitochondrial division. Pathological rates of mitochondrial fission in PAH may present an "Achilles heel" for these fast-growing cells. Inhibiting mitochondrial fission constitutes a novel therapeutic strategy in PAH.
